Biological properties of bone marrow plasma cells influence their recovery in aspirate specimens: impact on classification of plasma cell disorders and potential bias to evaluation of treatment response.


Journal

Annals of hematology
ISSN: 1432-0584
Titre abrégé: Ann Hematol
Pays: Germany
ID NLM: 9107334

Informations de publication

Date de publication:
Nov 2020
Historique:
received: 28 01 2020
accepted: 01 09 2020
pubmed: 17 9 2020
medline: 21 10 2020
entrez: 16 9 2020
Statut: ppublish

Résumé

Methods to estimate bone marrow plasma cells (BMPC) basically include histopathology, cytomorphology, and flow cytometry. The present study compares the outcomes of these methods with special focus on the impact of BMPC-specific characteristics on their recovery by either method. Laboratory reports of diagnostic samples from 238 consecutive patients with suspected or known plasma cell disease were retrospectively analyzed. The median (IQR) proportion of BMPC was 30.0% (15.0-70.0%) by histological review (hBMPC), 7.0% (2.0-16.0%) by smear review (sBMPC), and 3.0% (0.8-10.0%) by flow cytometry (fBMPC). The disparity of results between core biopsy and aspirate smear was enhanced in case of poor quality of the smear, increased BM fiber content, higher grade cell atypia, expression of CD56 (all P < 0.0001), the number of cytogenetic aberrations (P = 0.0002), and abnormalities of the MYC gene (P = 0.0002). Conversely, expression of CD19 and a non-clonal plasma cell phenotype were associated with a lower difference between hBMPC and sBMPC (both P < 0.0001). The disparity between the percentages of sBMPC and fBMPC was associated with the quality of the smear (P = 0.0007) and expression of CD56 (P < 0.0001). Our results suggest that the recovery of BMPC in aspirate specimens not only is a matter of sampling quality but also depends on biological cell properties. Aspiration failure due to malignant type features of BMPC may lead to misclassification of plasma cell disorders and represent a bias for the detection of minimal residual disease after therapy.

Identifiants

pubmed: 32935190
doi: 10.1007/s00277-020-04249-2
pii: 10.1007/s00277-020-04249-2
pmc: PMC7536141
doi:

Substances chimiques

Antigens, CD19 0
CD19 molecule, human 0
CD56 Antigen 0
NCAM1 protein, human 0
Neoplasm Proteins 0

Types de publication

Evaluation Study Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

2599-2609

Références

Lancet. 1986 Feb 8;1(8476):307-10
pubmed: 2868172
Int J Lab Hematol. 2015 Dec;37(6):797-808
pubmed: 26224420
Haematologica. 2008 Mar;93(3):431-8
pubmed: 18268286
Lancet Oncol. 2014 Nov;15(12):e538-48
pubmed: 25439696
Scand J Infect Dis. 1978;10(4):271-5
pubmed: 725539
Br J Haematol. 2016 Sep;174(5):818-20
pubmed: 26492094
Blood. 2013 Nov 21;122(22):3591-8
pubmed: 24072855
Blood. 2011 May 5;117(18):4691-5
pubmed: 21292775
Leuk Lymphoma. 2015 May;56(5):1416-24
pubmed: 25263319
Blood. 2002 Nov 1;100(9):3095-100
pubmed: 12384404
Cancer Res. 1995 Aug 15;55(16):3647-53
pubmed: 7543019
Br J Haematol. 2006 Jun;133(5):530-2
pubmed: 16681641
Br J Haematol. 1992 Sep;82(1):46-9
pubmed: 1419801
Pathol Biol (Paris). 1999 Feb;47(2):158-68
pubmed: 10192882
Diagn Pathol. 2010 May 18;5:30
pubmed: 20482792
Blood. 2005 Oct 1;106(7):2276-9
pubmed: 15961515
Blood Cancer J. 2017 Feb 17;7(2):e530
pubmed: 28211888
Haematologica. 2018 Nov;103(11):1772-1784
pubmed: 30171031
Leukemia. 2019 Aug;33(8):1851-1867
pubmed: 30696948
Cancer Genet Cytogenet. 2010 Dec;203(2):169-75
pubmed: 21156229
J Clin Pathol. 2008 Feb;61(2):213-6
pubmed: 17526802
Am J Clin Pathol. 2004 Apr;121(4):482-8
pubmed: 15080299
Blood. 1990 Jul 15;76(2):377-82
pubmed: 1695113
Br J Haematol. 1999 Jan;104(1):138-43
pubmed: 10027726
Clin Cancer Res. 2016 Nov 15;22(22):5428-5433
pubmed: 28151710
Hematol Oncol. 2017 Sep;35(3):323-328
pubmed: 27140172
Arch Pathol Lab Med. 2007 Jun;131(6):951-5
pubmed: 17550325
Lancet Oncol. 2016 Aug;17(8):e328-e346
pubmed: 27511158
Blood Cancer J. 2017 Oct 20;7(10):e617
pubmed: 29053157
Blood. 2007 Oct 1;110(7):2586-92
pubmed: 17576818

Auteurs

Svitlana Demyanets (S)

Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.

Alexandra Kaider (A)

Center for Medical Statistics, Informatics, and Intelligent Systems Section for Clinical Biometrics, Medical University of Vienna, Vienna, Austria.

Ingrid Simonitsch-Klupp (I)

Department of Pathology, Medical University of Vienna, Vienna, Austria.

Günther Bayer (G)

Department of Pathology, Medical University of Vienna, Vienna, Austria.

Almira Subasic (A)

Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.

Renate Thalhammer (R)

Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.

Harald Esterbauer (H)

Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.

Maria T Krauth (MT)

Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria.

Hermine Agis (H)

Department of Internal Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria.

Thomas Reiter (T)

Department of Internal Medicine III, Division of Nephrology and Dialysis, Medical University of Vienna, Vienna, Austria.

Ilse Schwarzinger (I)

Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria. ilse.schwarzinger@meduniwien.ac.at.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH